-
1 month ago | 
caixinglobal.com | Tang Hanyu |Zhou Xinda |Qing Na
Explore the story in 3 minutes[para. 1] In China, local governments have prioritized subsidizing various social insurance programs, including basic pensions and medical insurance. However, this initiative has put a significant strain on already financially burdened local budgets, prompting predictions that individuals may have to assume more responsibility for funding these programs. [para. 2][para.
-
1 month ago | 
caixinglobal.com | Tang Hanyu |Zhou Xinda |Qing Na
Explore the story in 3 minutes[para. 1] In China, local governments have prioritized subsidizing various social insurance programs, including basic pensions and medical insurance. However, this initiative has put a significant strain on already financially burdened local budgets, prompting predictions that individuals may have to assume more responsibility for funding these programs. [para. 2][para.
-
2 months ago | 
caixinglobal.com | Kelly Wang |Zhou Xinda
00:00/00:00 您的浏览器不支持 audio 标签。 Listen to this article 1x China’s national health insurance and medicine regulators have defended the quality of drugs procured through the country’s central bulk-buying program, rebutting claims from medical professionals earlier this year that some of the medications had been less effective than advertised.
-
2 months ago | 
caixinglobal.com | Kelly Wang |Zhou Xinda
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
China’s national health insurance and medicine regulators have defended the quality of drugs procured through the country’s central bulk-buying program, rebutting claims from medical professionals earlier this year that some of the medications had been less effective than advertised.
-
2 months ago | 
caixinglobal.com | Zhou Xinda |Kelly Wang
00:00/00:00 您的浏览器不支持 audio 标签。 Listen to this article 1x Beijing and Tianjin are among a growing number of Chinese cities reporting deficits in their medical insurance funds for residents, as the country continues to grapple with an aging population, rising health care costs and slowing government revenue growth. China’s capital had an annual deficit of 525.6 million yuan ($72.1 million) in its resident medical insurance fund, according to its 2024 municipal budget.
-
2 months ago | 
caixinglobal.com | Zhou Xinda |Kelly Wang
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
Beijing and Tianjin are among a growing number of Chinese cities reporting deficits in their medical insurance funds for residents, as the country continues to grapple with an aging population, rising health care costs and slowing government revenue growth.
-
2 months ago | 
caixinglobal.com | Zhou Xinda |Cui Xiaotian |Jiang Moting |Kelly Wang
Personalised advertising and content, advertising and content measurement, audience research and services developmentStore and/or access information on a deviceYou can choose how your personal data is used.
-
2 months ago | 
caixinglobal.com | Zhou Xinda |Cui Xiaotian |Jiang Moting |Kelly Wang
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
In a bid to lower the prices the Chinese state and public pay for medicines, Beijing implemented its centralized procurement policy in 2018. Under this system, the drugs are included by China’s state-run health care insurance and negotiated on a national basis.
Ever since, it’s been fiercely debated whether or not the hard bargains driven by the government undermine drugs’ quality.
-
Jan 17, 2025 | 
caixinglobal.com | Zhou Xinda |Zhao Jinzhao |Guo Xin
Indonesia, Southeast Asia’s largest economy, is turning into a critical entry point for Chinese drugmakers looking to expand overseas.
However, the archipelago nation has presented them with challenges, along with the opportunities.
Chinese drug producers have been under mounting pressure to find new sources of growth abroad as government measures to lower drug prices have squeezed profit margins. Indonesia presents possibilities.
You've accessed an article available only to subscribers
-
Jan 17, 2025 | 
caixinglobal.com | Zhou Xinda |Zhao Jinzhao |Guo Xin
Indonesia, Southeast Asia’s largest economy, is turning into a critical entry point for Chinese drugmakers looking to expand overseas. However, the archipelago nation has presented them with challenges, along with the opportunities. Chinese drug producers have been under mounting pressure to find new sources of growth abroad as government measures to lower drug prices have squeezed profit margins. Indonesia presents possibilities. You've accessed an article available only to subscribers
